Nanobiotix S.A. Stock Price, News & Analysis

Nanobiotix has announced significant progress in its global collaboration with Janssen to develop and commercialize its radioenhancer NBTXR3. This collaboration aims to expand the application of NBTXR3 in treating cancer patients who undergo radiotherapy. Key updates include the removal of a planned futility analysis for the ongoing Phase 3 head and neck cancer trial, with interim analysis results expected in 1H2026. Additionally, the company received FDA approval to proceed with a new Phase 2 study for lung cancer. These advancements are part of a broader strategy to leverage NBTXR3’s potential to fund the development of other nanoparticle-based therapies. Nanobiotix is also aligning with Janssen on global manufacturing and operational strategies, including a transfer of trial sponsorship to Janssen and a focus on expanding indications beyond head and neck and lung cancer.

Nanobiotix has disclosed updated information on its share capital and voting rights in compliance with French regulations. As of April 30, 2024, the company has 47,133,328 outstanding shares. The total number of theoretical voting rights is 48,903,298, while exercisable voting rights stand at 48,881,180. This update follows Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority. Nanobiotix will continue to publish monthly updates if there are changes in these figures.

NANOBIOTIX (Euronext: NANO, NASDAQ: NBTX), a late-clinical stage biotechnology company, will announce its Q1 2024 financial and operational results on May 22, 2024, before US and EU markets open.

The announcement will be followed by a conference call and webcast at 8:00 am EDT / 2:00 pm CEST, featuring CEO Laurent Levy and CFO Bart van Rhijn, who will review the results and provide a business update.

The company's next Annual General Meeting (AGM) is scheduled for May 28, 2024, at its Paris headquarters. Meeting details and related documents are available on NANOBIOTIX's website.

NANOBIOTIX has announced that the US FDA has issued a Study May Proceed Letter for a new Phase 2 study evaluating NBTXR3 in patients with stage 3, unresectable non-small cell lung cancer (NSCLC). The study is sponsored by Johnson & Johnson Enterprise Innovation Inc., a subsidiary of Johnson & Johnson. This progress is part of Nanobiotix's global licensing agreement with Janssen Pharmaceutica NV, aimed at expanding the application of NBTXR3 to new cancer indications. The acceptance of this protocol by the FDA is seen as a significant step towards potentially providing improved treatment outcomes for a new group of cancer patients.